Inmed announces publication of peer-reviewed study highlighting potential role of rare cannabinoids thcv, cbc and others on skin conditions

Vancouver, british columbia, june 14, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific study entitled “effects of rare phytocannabinoids on the endocannabinoid system of human keratinocytes” has been published in the international journal of molecular sciences. the study, in collaboration with dr. mauro maccarrone, professor and chair of biochemistry at the department of biotechnological and applied clinical sciences, university of l'aquila, italy, highlights the biological activity of tetrahydrocannabivarin (“thcv”), cannabichromene (“cbc”) and other rare cannabinoids and their potential role in addressing various skin conditions.
INM Ratings Summary
INM Quant Ranking